Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ANI Pharmaceuticals (ANIP)

ANI Pharmaceuticals stockholders elect seven directors and approve amended stock plan

Neutral Impact 2 of 5 shareholder Written later

At its 2026 Annual Meeting on May 21, 2026, ANI Pharmaceuticals stockholders elected seven directors, ratified Ernst & Young LLP as the independent auditor for fiscal 2026, approved executive pay on an advisory basis, and approved the Amended and Restated 2022 Stock Incentive Plan. The company will hold advisory votes on executive pay every year, following the stockholders' frequency vote. The filing covers governance matters only and includes no financial results or guidance.

Key points

  • Amended 2022 Stock Incentive Plan approved: 13,806,050 for, 1,080,387 against, 9,388 abstain, 2,030,222 broker non-votes
  • Advisory say-on-pay proposal approved: 13,819,988 for and 1,058,460 against
  • Stockholders voted 14,412,299 for an annual advisory pay vote; the board will hold these votes every one year
  • Ernst & Young LLP ratified as auditor for fiscal year ending December 31, 2026: 16,874,103 for and 7,333 against

The filing

CompanyANI Pharmaceuticals (ANIP)
Form8-K, current report
Filed with the SECMay 21, 2026, 4:13 PM ET
Accession number0001023024-26-000056

Items reported: 5.02 Director / Officer Change5.07 Shareholder Vote Results

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 21, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.